A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults

NCT03473002 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

NIH

Sponsor class

Conditions

Antiviral Prophylaxis
Respiratory Syncytial Virus Infection

Interventions

OTHER: Placebo
BIOLOGICAL: SeVRSV Vaccine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)